Search

Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
Corporate Responsibility
Our Products & Pipeline
Gene Therapy Engine
RNA Platform
Our Disease Areas
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) (ENVISION)
A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)